Avacincaptad pegol (ARC1905) is an anti-C5 RNA aptamer that inhibits the cleavage of complement factor 5 (C5) into C5a and C5b. Avacincaptad pegol is being used for the study of age-related macular degeneration (AMD).
References:
[1]. Jaffe GJ, Westby K, Csaky KG, et al. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.Ophthalmology. 2021;128(4):576-586.
[2]. Patel SS, Lally DR, Hsu J, et al. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial [published online ahead of print, 2023 Mar 24].Eye (Lond). 2023;10.1038/s41433-023-02497-w.
[3]. Powers, J. P., Dairaghi, D. J., & Jaen, J. C. (2011). Advances in the Discovery of C5a Receptor Antagonists. Annual Reports in Medicinal Chemistry, 171–186.
















